OR] 2.09; 1.01-4.35;P for trend = 0.048).Finally, in a subgroup analysis of patients with high u-sCD11b levels, those who received immunosuppressive therapy exhibited a significantly slower decline in eGFR from baseline over a 2-year follow-up period compared to the untreated patients. Conclusion:This study provides strong initial evidence that u-sCD11b levels are associated with clinical severity, active pathological lesions, and short-term remission status in IgAN.Furthermore, elevated u-sCD11b may signify active inflammatory states that warrant more aggressive immunosuppressive therapy.Collectively, our findings position u-sCD11b as a novel and valuable biomarker for assessing disease activity, predicting short-term outcomes, and informing management strategies in patients with IgAN.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Tang et al. (Wed,) studied this question.